Drugs / AZD2927
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01264250 | Jan → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01396226 | Sep 2011 → Jan 2012 | cardiac rhythm disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2927 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01396226 ↗ |
| Known as | Ccr2 antagonist 3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314950 ↗ |
| Modality | Small molecule | — CHEMBL5314950 ↗ |
| Route | Intravenous | “Intravenous Doses” NCT01264250 ↗ |